Research programme: viral nuclear importation inhibitors - Ferring Pharmaceuticals

Drug Profile

Research programme: viral nuclear importation inhibitors - Ferring Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Cytokine PharmaSciences
  • Class Small molecules
  • Mechanism of Action Nuclear importation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA
  • 20 Oct 2011 Cytokine PharmaSciences has been acquired by Ferring Pharmaceuticals
  • 01 Jun 2010 The small molecule viral nuclear importation inhibitors are available for licensing (http://www.cytokinepharmasciences.com/next-nuclear-importation-inhibitors.shtml)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top